Neogen Corporation Amortization of Intangible Assets
Neogen Corporation (NEOG) reported Amortization of Intangible Assets of $91.80 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-07-30
- Neogen Corporation amortization of intangible assets for the quarter ending 2024-05-31 was $23.80M, a 3.07% increase year-over-year.
- Neogen Corporation amortization of intangible assets for the quarter ending 2024-02-29 was $23.70M, a 3.39% increase year-over-year.
- Neogen Corporation amortization of intangible assets for the quarter ending 2023-11-30 was $23.69M, a 4.43% increase year-over-year.
- Neogen Corporation amortization of intangible assets for the quarter ending 2023-08-31 was $23.70M, a 895.13% increase year-over-year.
- Neogen Corporation amortization of intangible assets for fiscal 2026 was $91.80M, a 2.24% decline from fiscal 2025.
- Neogen Corporation amortization of intangible assets for fiscal 2025 was $93.90M, a 1.05% decline from fiscal 2024.
- Neogen Corporation amortization of intangible assets for fiscal 2024 was $94.90M, a 33.50% increase from fiscal 2023.
- Neogen Corporation amortization of intangible assets for fiscal 2023 was $71.08M, a 640.47% increase from fiscal 2022.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $91.80M 10-K · filed 2026-07-30 | |||||||
| 2025-05-31 | $93.90M 10-K · filed 2026-07-30 | $93.92M 10-K · filed 2025-07-30 | ||||||
| 2024-05-31 | $23.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $47.50M derived: sum of 2 quarters · filed 2026-07-30 | $71.20M derived: sum of 3 quarters · filed 2026-07-30 | $94.90M 10-K · filed 2026-07-30 | $94.95M 10-K · filed 2024-07-30 | |||
| 2024-02-29 | $23.70M 10-Q · filed 2024-04-09 | $47.40M derived: sum of 2 quarters · filed 2024-04-09 | $71.10M 10-Q · filed 2024-04-09 | $94.19M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-11-30 | $23.69M 10-Q · filed 2024-01-09 | $47.40M 10-Q · filed 2024-01-09 | $70.49M derived: sum of 3 quarters · filed 2025-07-30 | $93.41M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-08-31 | $23.70M 10-Q · filed 2023-10-10 | $46.79M derived: sum of 2 quarters · filed 2025-07-30 | $69.72M derived: sum of 3 quarters · filed 2025-07-30 | $92.41M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-05-31 | $23.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $46.02M derived: sum of 2 quarters · filed 2025-07-30 | $68.70M derived: sum of 3 quarters · filed 2025-07-30 | $71.08M 10-K · filed 2025-07-30 | ||||
| 2023-02-28 | $22.93M 10-Q · filed 2024-04-09 | $22.90M 10-Q · filed 2023-04-04 | $45.61M derived: sum of 2 quarters · filed 2024-04-09 | $47.99M 10-Q · filed 2024-04-09 | $48.00M 10-Q · filed 2023-04-04 | $50.30M derived: sum of 4 quarters · filed 2024-07-30 | ||
| 2022-11-30 | $22.69M 10-Q · filed 2024-01-09 | $22.70M 10-Q · filed 2023-01-09 | $25.07M 10-Q · filed 2024-01-09 | $25.10M 10-Q · filed 2023-01-09 | $27.37M derived: sum of 3 quarters · filed 2024-07-30 | $29.97M derived: sum of 4 quarters · filed 2024-07-30 | ||
| 2022-08-31 | $2.38M 10-Q · filed 2023-10-10 | $4.68M derived: sum of 2 quarters · filed 2024-07-30 | $7.28M derived: sum of 3 quarters · filed 2024-07-30 | $9.68M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-05-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $4.90M derived: sum of 2 quarters · filed 2024-07-30 | $7.30M derived: sum of 3 quarters · filed 2024-07-30 | $9.60M 10-K · filed 2024-07-30 | ||||
| 2022-02-28 | $2.60M 10-Q · filed 2023-04-04 | $5.00M derived: sum of 2 quarters · filed 2023-04-04 | $7.30M 10-Q · filed 2023-04-04 | |||||
| 2021-11-30 | $2.40M 10-Q · filed 2023-01-09 | $4.60M 10-Q · filed 2023-01-09 | ||||||
| 2021-05-31 | $7.75M 10-K · filed 2023-08-15 | |||||||
| 2020-05-31 | $6.49M 10-K · filed 2022-07-27 | |||||||
| 2019-05-31 | $6.31M 10-K · filed 2021-07-30 | |||||||
| 2018-05-31 | $6.74M 10-K · filed 2020-07-30 | |||||||
| 2017-05-31 | $5.91M 10-K · filed 2018-07-27 | |||||||
| 2016-05-31 | $5.91M 10-K · filed 2019-07-30 | $5.09M 10-K · filed 2016-07-29 | ||||||
| 2015-05-31 | $4.33M 10-K · filed 2017-07-28 | |||||||
| 2014-05-31 | $3.80M 10-K · filed 2016-07-29 | |||||||
| 2013-05-31 | $2.99M 10-K · filed 2015-07-30 | |||||||
| 2012-05-31 | $2.53M 10-K · filed 2014-07-30 | $2.54M 10-K · filed 2012-07-30 | ||||||
| 2011-05-31 | $2.14M 10-K · filed 2013-07-30 | |||||||
| 2010-05-31 | $1.70M 10-K · filed 2012-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |